SCHEMBL24978397

SCHEMBL24978397

O=C(Cl)OCCCN1C(=O)C=CC1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 9/20 0.54
FAAH O00519 6/20 0.54
ALDH1A1 P00352 2/20 0.52
HPGD P15428 2/20 0.52
HSP90AA1 P07900 1/20 0.52
TLR9 Q9NR96 1/20 0.52
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.52
MAPT P10636 1/20 0.52
PKM P14618 1/20 0.52
XBP1 P17861 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
RECQL P46063 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
GPR35 Q9HC97 1/20 0.52
GPR55 Q9Y2T6 1/20 0.52
PTGS1 P23219 7/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21348323 0.93 MGLL (0.59) MGLLFAAHALDH1A1HPGDHSP90AA1
SCHEMBL6753848 0.89 MGLL (0.55) MGLLFAAHALDH1A1HPGDHSP90AA1
SCHEMBL7096979 0.85 MGLL (0.58) MGLLFAAHALDH1A1HPGDHSP90AA1
SCHEMBL24978398 0.83 MGLL (0.56) MGLLFAAHALDH1A1HPGDHSP90AA1
SCHEMBL8088363 0.81 MGLL (0.54) MGLLFAAHALDH1A1HPGDHSP90AA1
SCHEMBL28633544 0.81 MGLL (0.54) MGLLFAAHALDH1A1HPGDHSP90AA1
SCHEMBL8888140 0.80 MGLL (0.52) MGLLFAAHALDH1A1HPGDHSP90AA1
SCHEMBL6534708 0.80 MGLL (0.42) MGLLFAAHALDH1A1HPGDHSP90AA1
SCHEMBL5361313 0.79 MGLL (0.61) MGLLFAAHALDH1A1HPGDHSP90AA1
SCHEMBL24978575 0.79 MGLL (0.50) MGLLFAAHALDH1A1HPGDHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226313-A1 CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF SEAGEN INC. 2024-07-11 US disclosed
US-20240226313-A1 CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF SEAGEN INC. 2024-07-11 US disclosed
US-20230036256-A1 CAMPTOTHECIN CONJUGATES SEAGEN INC. 2023-02-02 US disclosed
CN-115636863-A Dexamethasone derivative containing maleimide segment and preparation method thereof 中国医学科学院医药生物技术研究所 2023-01-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226313-A1 CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF EPCAM, TOP2A, SPAG5 MGLL 4028/4885FAAH 3433/4885ALDH1A1 388/4885
US-20230036256-A1 CAMPTOTHECIN CONJUGATES DCLRE1A, TOP2A, PAICS MGLL 4556/4885FAAH 4082/4885ALDH1A1 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.